Neurizon Therapeutics Moves Forward with ALS Trial

Pharmaust Limited (AU:NUZ) has released an update.

Neurizon Therapeutics Limited has filed an Investigational New Drug application with the FDA for its lead candidate, NUZ-001, to commence a Phase 2/3 clinical trial targeting ALS. This marks a significant milestone in the company’s efforts to address neurodegenerative diseases and could provide new hope for ALS patients. The trial is set to begin in the first half of 2025, pending FDA approval.

For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.